GO:0044325 transmembrane transporter binding: Mechanism, Genes and Research Methods

Research-grade guide for scientists and biopharma professionals

Key Takeaways

GO:0044325 (transmembrane transporter binding) is a molecular function describing the binding of a protein to a transmembrane transporter, a protein or complex that moves substances across a membrane.
The term is synonymous with ion channel binding and is distinct from transporter activity itself; it captures regulatory, scaffolding, and assembly interactions.
Transmembrane transporter binding is central to diverse physiological processes, including nutrient uptake, ion homeostasis, hormone transport, and drug disposition [2,5].
Dysregulation of these interactions contributes to diseases such as cancer, neurological disorders, and metabolic syndromes [2,5].
Key experimental approaches include knockout, point-mutation, knock-in, and overexpression models, combined with biochemical binding assays and structural biology [3,4,7].
EDITGENE provides comprehensive CRISPR services to dissect transmembrane transporter binding mechanisms and validate therapeutic targets [3,4,8].

Description

Transmembrane transporter binding (GO:0044325) is a molecular function that defines the physical interaction between a protein and a transmembrane transporter, which is a protein or protein complex that facilitates the movement of substances across a membrane. This binding event is fundamental to the regulation, assembly, and functional modulation of transporters, impacting a wide array of biological processes from nutrient uptake to signal transduction [2,5]. Understanding these interactions is crucial for researchers aiming to decipher cellular physiology and develop targeted therapeutics [2,5]. The term is often used interchangeably with ion channel binding, reflecting its broad relevance to membrane transport systems. In this article, we explore the definition, mechanisms, key genes, and research methodologies associated with GO:0044325, providing a comprehensive resource for biomedical scientists [3,4,7].

transmembrane transporter binding At A Glance

GO ID GO:0044325
GO term transmembrane transporter binding
Ontology molecular_function
Synonym ion channel binding
Major function Binding to transmembrane transporters to modulate their activity, assembly, or localization
Related processes Transport, signal transduction, homeostasis
Examples Binding to ABC transporters, urea transporters, P-type ATPases

What Is GO:0044325?

GO:0044325, transmembrane transporter binding, is defined as the binding to a transmembrane transporter, a protein or protein complex that enables the transfer of a substance, usually a specific substance or a group of related substances, from one side of a membrane to the other. This molecular function encompasses interactions that may regulate transporter activity, localization, or stability, and is synonymous with ion channel binding.

Why Is transmembrane transporter binding Important in Cell Biology?

Transmembrane transporter binding is essential for understanding how cells regulate the movement of ions, nutrients, and drugs across membranes [2,5]. This function impacts drug pharmacokinetics, hormone signaling, and cellular stress responses, making it a critical area of study for pharmacology, physiology, and disease research [2,5].
Regulates transporter activity and substrate specificity, influencing cellular uptake and efflux.
Modulates drug transport and pharmacokinetics, affecting therapeutic efficacy and toxicity.
Controls ion homeostasis and membrane potential, critical for neuronal and cardiac function.
Participates in hormone transport, such as thyroid hormones, impacting metabolism.
Involved in lipid-mediated regulation of transporter function.
Dysregulation linked to cancer, neurological disorders, and metabolic diseases [2,5].
Provides targets for pharmacological intervention in transport-related pathologies.
Essential for understanding membrane protein assembly and quality control.
Facilitates structural studies of transporter complexes [3,7].
Enables CRISPR-based functional genomics of transport systems [3,4,8].

What Happens During transmembrane transporter binding?

Recognition and Initial Contact
In simple terms: The binding protein finds and attaches to a specific transporter on the membrane.
The process begins with the recognition of a transmembrane transporter by a binding partner, often through electrostatic or hydrophobic interactions. This initial contact can be influenced by membrane lipid composition, which affects transporter conformation and accessibility. For example, lipoprotein recognition by LolCDE involves specific binding events that are essential for transport.
Conformational Changes and Complex Formation
In simple terms: Binding causes shape changes in the transporter, leading to a stable complex.
Upon binding, conformational changes in the transporter can occur, leading to the formation of a stable complex that may modulate transport activity [3,7]. Structural studies of urea transporters have revealed distinct inhibition modes upon binding of regulatory proteins. Similarly, P-type ATPases like ERMA undergo conformational transitions during Mg2+ uptake, which are regulated by binding partners.
Functional Modulation of Transport
In simple terms: The binding event can turn the transporter on or off, or change what it transports.
Binding can enhance or inhibit transporter activity, alter substrate specificity, or affect trafficking to the membrane [2,5]. For instance, thyroid hormone transport is modulated by binding proteins that influence transporter function. In drug transport, binding interactions can lead to natural product-drug interactions.
Downstream Signaling and Cellular Responses
In simple terms: The binding triggers signals inside the cell that change its behavior.
Transmembrane transporter binding can initiate signaling cascades that affect gene expression, metabolism, or cell survival [1,5]. This is particularly relevant in cancer, where transporter-binding proteins can promote drug resistance or tumor growth.

Key Genes Involved in GO:0044325 transmembrane transporter binding

The following genes encode proteins that are known to bind transmembrane transporters or are themselves transporters involved in binding interactions, based on published literature [1-8].
GeneMajor RoleResearch Relevance
ABCB1ATP-binding cassette transporter; binds various substrates and regulatory proteinsDrug resistance, pharmacokinetics [1,2]
SLC14A1Urea transporter; binding regulates urea permeationKidney function, urea cycle disorders
ATP2C1P-type ATPase; binds Mg2+ and regulatory proteinsMagnesium homeostasis, ER function
LolCDELipoprotein transporter complex; binds lipoproteinsBacterial lipoprotein transport
THRAThyroid hormone receptor; binds thyroid hormones and transportersThyroid hormone transport
CFTRChloride channel; binds regulatory proteinsCystic fibrosis, ion transport
KCNQ1Potassium channel; binds auxiliary subunitsCardiac arrhythmia
SCN5ASodium channel; binds regulatory proteinsBrugada syndrome
ATP1A1Na+/K+-ATPase; binds regulatory proteinsIon homeostasis
SLC2A1Glucose transporter; binds regulatory proteinsGLUT1 deficiency
SLC22A1Organic cation transporter; binds drugsDrug disposition
ABCC2Multidrug resistance protein; binds substratesBiliary transport
SLC7A11Cystine/glutamate transporter; binds regulatory proteinsCancer metabolism
TMEM94ER Mg2+ transporter; binds Mg2+ER homeostasis
SLC5A5Sodium-iodide symporter; binds ionsThyroid function
ABCB11Bile salt export pump; binds bile saltsCholestasis
SLC6A4Serotonin transporter; binds antidepressantsDepression, drug response

How Is transmembrane transporter binding Regulated?

Transmembrane transporter binding is regulated by various factors, including membrane lipid composition, post-translational modifications, and interacting proteins. For example, membrane lipids can directly modulate transporter function by altering binding affinities. Additionally, hormonal signals such as thyroid hormones can regulate the expression and activity of transporters and their binding partners. In bacteria, lipoprotein transport is tightly regulated by the LolCDE complex.

transmembrane transporter binding and Human Disease

GeneDisease / BiologyPotential Experimental Model
ABCB1Multidrug resistance in cancerKnockout in cancer cell lines, drug sensitivity assays
SLC14A1Urea cycle disorders, kidney dysfunctionPoint mutation knock-in in HEK293 cells, urea transport assays
ATP2C1Hailey-Hailey disease, Mg2+ imbalanceKnockout in keratinocytes, Ca2+ imaging
KCNQ1Long QT syndrome, arrhythmiaKnock-in of patient mutations in iPSC-derived cardiomyocytes
LolCDEBacterial infectionsKnockout in E. coli, lipoprotein transport assays
Cancer and Drug Resistance
Altered transmembrane transporter binding can lead to multidrug resistance in cancer cells, as transporters like ABCB1 efflux chemotherapeutic agents. Binding proteins may enhance or inhibit this efflux, influencing treatment outcomes.
Neurological Disorders
Ion channel binding is critical for neuronal excitability; mutations in binding interfaces can cause epilepsy or arrhythmias. For instance, KCNQ1 binding partners affect cardiac action potentials.
Metabolic and Endocrine Diseases
Thyroid hormone transport relies on specific transporter-binding interactions; disruptions can lead to hypothyroidism or resistance. Similarly, urea transporter binding defects cause kidney disorders.
Infectious Diseases
Bacterial lipoprotein transport via LolCDE is essential for viability; binding inhibitors are potential antibiotics.

From transmembrane transporter binding-Related Genes to Experimental Models

Research QuestionSuitable Model
Does gene X bind to transporter Y?Knockout of gene X, co-immunoprecipitation
What is the affinity of binding?Point mutations in binding interface, surface plasmon resonance
Does binding regulate transport activity?Overexpression of binding protein, transport assays
Where does binding occur in the cell?Tagged knock-in, fluorescence microscopy
What are the downstream effects of binding?Knockout + RNA-seq, proteomics
Can binding be targeted therapeutically?Overexpression of dominant-negative mutant, drug screening

How to Study the transmembrane transporter binding Process

MethodWhat It MeasuresTypical Application
Co-immunoprecipitationProtein-protein interactionsIdentifying binding partners
Surface plasmon resonanceBinding affinity and kineticsQuantifying interactions
Cryo-EM3D structure of complexesVisualizing binding interfaces
Transport assaysSubstrate fluxFunctional impact of binding
CRISPR knockoutLoss-of-function effectsValidating gene function
RNA-seqTranscriptional changesDownstream signaling
ProteomicsProtein abundance and modificationsGlobal binding networks
Biochemical Binding Assays
Co-immunoprecipitation, pull-down, and surface plasmon resonance are used to detect and quantify binding between proteins and transporters [1,4].
Structural Biology
Cryo-EM and X-ray crystallography reveal atomic details of transporter-binding complexes, as shown for urea transporters and LolCDE [4,7].
Functional Transport Assays
Radiolabeled substrate uptake or efflux assays measure how binding affects transport activity [2,5].
Genetic and Genomic Approaches
CRISPR knockout, knock-in, and overexpression models combined with RNA-seq or proteomics identify binding partners and downstream effects [3,8].

How CRISPR Can Be Used to Study GO:0044325 transmembrane transporter binding

Knockout

CRISPR knockout of genes encoding transporters or their binding partners can reveal loss-of-function phenotypes, such as altered transport activity or drug sensitivity [3,8].

Point Mutation

Introducing point mutations in binding interfaces via CRISPR can dissect specific residues critical for interaction, as demonstrated for P-type ATPases.

Knock-in

Knock-in of tagged or mutant versions of transporters allows tracking of localization and binding dynamics in live cells.

Overexpression

Overexpression of binding proteins or transporters can amplify binding effects, useful for biochemical and structural studies [2,7].

How EDITGENE Supports transmembrane transporter binding Research

Researchers studying transmembrane transporter binding-related genes often need to determine whether a candidate gene is causally involved in transport regulation, disease progression, or drug response. EDITGENE provides end-to-end CRISPR solutions to generate precisely engineered cell models, enabling functional validation and mechanistic insights.
Contact EDITGENE today to design your custom CRISPR model for transmembrane transporter binding research.

Frequently Asked Questions About transmembrane transporter binding

It is a molecular function (GO:0044325) where a protein binds to a transmembrane transporter, regulating its activity or assembly.
Genes include ABCB1, SLC14A1, ATP2C1, and many others encoding transporters or their binding partners [1-8].
Common methods include co-immunoprecipitation, structural biology, transport assays, and CRISPR screens [3,4,7].
It affects drug efflux and resistance; binding proteins can modulate ABC transporter activity.
Cancer, neurological disorders, metabolic diseases, and infections [2,5,7].
Yes, knockout, knock-in, and point mutation models help dissect binding mechanisms [3,8].
Ion channel binding.
QuickGO and PubMed literature [1-8].
Lipids can alter transporter conformation and binding affinity.
Transporters and their binding interfaces, especially in cancer and infections [2,4].

Conclusion

Transmembrane transporter binding (GO:0044325) is a fundamental molecular function that governs the regulation of membrane transport systems. Its implications span physiology, pharmacology, and disease, making it a vibrant area of research. Leveraging CRISPR-based models and biochemical assays, scientists can unravel the complexities of these interactions and identify new therapeutic targets. EDITGENE offers comprehensive services to support these endeavors, from knockout to overexpression and screening.

References

  1. 1. Rea PA. 2007. Plant ATP-binding cassette transporters.. Annu Rev Plant Biol 58:347-75 PMID: 17263663
  2. 2. Bi Y et al.. 2023. Transporter-mediated Natural Product-Drug Interactions.. Planta Med 89(2):119-133 PMID: 35304735
  3. 3. Santarossa CC et al.. 2026. LetA defines a structurally distinct transporter family.. Nature 651(8107):1097-1106 PMID: 41565823
  4. 4. Qiao W et al.. 2024. Deciphering the molecular basis of lipoprotein recognition and transport by LolCDE.. Signal Transduct Target Ther 9(1):354 PMID: 39725716
  5. 5. Braun D et al.. 2018. Thyroid Hormone Transport and Transporters.. Vitam Horm 106:19-44 PMID: 29407435
  6. 6. Stieger B et al.. 2021. Membrane lipids and transporter function.. Biochim Biophys Acta Mol Basis Dis 1867(5):166079 PMID: 33476785
  7. 7. Huang SM et al.. 2024. Structural insights into the mechanisms of urea permeation and distinct inhibition modes of urea transporters.. Nat Commun 15(1):10226 PMID: 39587082
  8. 8. Vishnu N et al.. 2024. ERMA (TMEM94) is a P-type ATPase transporter for Mg(2+) uptake in the endoplasmic reticulum.. Mol Cell 84(7):1321-1337.e11 PMID: 38513662
Contact Us
*
*
*
*
How did you hear about us: